When considering an intervention such as VTE prophylaxis that is intended for prevention as opposed to treatment, the risks and benefits must be carefully weighed. The efficacy of thromboprophylaxis has been established for orthopedic populations; presumably it would be similarly effective in podiatric patients. In patients who are at high risk for VTE, the benefits of thromboprophylaxis will generally outweigh the risks. However, in patients who are at low risk for VTE, the risk/benefit ratio may not be obvious. Bleeding, although infrequent, is increasingly recognized to be associated with adverse outcomes, increased cost, and, potentially, an inability to resume therapy with needed anticoagulants. Thus, an accurate and careful evaluation of a patient's thrombotic risk is essential to avoid unnecessary or potentially harmful administration of medications.